Skip to Content

Merck KGaA MRK Stock Quote

| Rating as of

Morningstar‘s Stock Analysis MRK

Currency in EUR
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Merck KGaA's Prospects Remain Solid, Although COVID-19 Benefits May Not Last

Julie Utterback, CFA Senior Equity Analyst

Business Strategy and Outlook

| Julie Utterback, CFA |

Merck KGaA has made a series of acquisitions and divestitures in the past decade or so to position the group for solid long-term growth in three key segments: life sciences, performance materials, and healthcare. However, after robust results in 2020 and 2021 due to COVID-19-related benefits particularly in its life sciences business, we think the company's intermediate-term growth may soften toward more historic norms.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics MRK

Company Profile MRK

Business Description

Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (46% of 2021 sales) provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (36%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

Frankfurter Strasse 250
Darmstadt, HE, 64293, Germany
T +49 6151720
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 62,770